Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

According to a new feature by the Washington Post, approximately 16 million American adults are on GLP-1 drugs such as ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...